RWE(Real World Evidence) 솔루션 시장 : 컴포넌트, 용도, 매출 모델, 도입 모델, 최종사용자별, 예측(2024-2032년)

The Real-World Evidence Solutions Market size will expand at 15.7% CAGR during 2024-2032, driven by the increasing prevalence of chronic diseases. According to the CDC data, annually, over 934,500 Americans die from heart disease or stroke, representing more than one in four deaths. While cancer is diagnosed in 1.7 million people, with over 600,000 fatalities. Additionally, more than 38 million Americans have diabetes, and 98 million adults have prediabetes.

Real world evidence plays a crucial role in understanding disease patterns, treatment outcomes, and patient management practices in real-world settings. By analyzing large-scale data sets from diverse sources, including electronic health records (EHRs) and patient registries, stakeholders can identify trends, assess treatment effectiveness, and develop targeted interventions to improve patient outcomes. The integration of RWE into clinical research and healthcare delivery is essential for addressing the complex challenges posed by chronic diseases and optimizing healthcare resources efficiently. Further, the trend of personalized medicine and patient-centric care will augment the market outlook.

The real-world evidence solutions industry is classified based on component, application, revenue model, deployment model, end-user, and region.

The post-market surveillance segment will grow rapidly through 2032. The post-market surveillance (PMS) involves monitoring the efficacy of medical products after they have been approved. PMS utilizes real-world data to detect adverse events, assess product performance, and ensure regulatory compliance. By leveraging RWE solutions, healthcare stakeholders can conduct comprehensive surveillance activities, identify potential safety concerns early, and implement necessary interventions to protect patient health.

The data sets component segment share will record notable surge by 2032. The data sets encompass diverse sources such as electronic health records (EHRs), claims data, patient registries, and wearable devices. By aggregating and analyzing these data sets, stakeholders can derive comprehensive insights into disease patterns, treatment effectiveness, and patient outcomes in real-world settings. Advanced data integration and interoperability solutions facilitate the harmonization of disparate data sets, enabling seamless analysis and decision-making across healthcare organizations and research institutions.

Europe real world evidence solutions industry will grow at a steady pace through 2032, driven by a robust healthcare infrastructure, supportive regulatory environment, and increasing adoption of digital health technologies. The European Medicines Agency (EMA) and national regulatory authorities encourage the use of RWE in regulatory decision-making, further stimulating market growth. Additionally, collaborations between academic institutions, healthcare providers, and pharmaceutical companies in Europe are promoting the development of RWE-based research initiatives and clinical trials, adding to market value.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing focus towards accelerating drug development and cost reduction
    • 3.2.1.2 Growing demand for real-time safety and efficacy monitoring of drugs and medical devices
    • 3.2.1.3 Increasing adoption of RWE Solutions for informed reimbursement decision-making
    • 3.2.1.4 Increasing adoption of data analytics services in clinical decision making
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Lack of standardization in integration and interoperability of real-world data
    • 3.2.2.2 Shortage of skilled professionals
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Services
• 5.3 Data sets
  • 5.3.1 Disparate data sets
    • 5.3.1.1 Clinical settings data sets
    • 5.3.1.2 Claims data sets
    • 5.3.1.3 Pharmacy data sets
    • 5.3.1.4 Patient powered data sets
    • 5.3.1.5 Registry-based data sets
  • 5.3.2 Integrated data sets

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug development and approvals
  • 6.2.1 Oncology
  • 6.2.2 Cardiovascular disease
  • 6.2.3 Neurology
  • 6.2.4 Immunology
  • 6.2.5 Other therapeutic areas
• 6.3 Medical device development and approvals
• 6.4 Post-market surveillance
• 6.5 Market access & reimbursement/coverage decision-making
• 6.6 Clinical & regulatory decision-making

Chapter 7 Market Estimates and Forecast, By Revenue Model, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pay-per-use (value-based pricing)
• 7.3 Subscription

Chapter 8 Market Estimates and Forecast, By Deployment Model, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 On-premise
• 8.3 Cloud-based

Chapter 9 Market Estimates and Forecast, By End User, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and medical device companies
• 9.3 Healthcare payers
• 9.4 Healthcare providers
• 9.5 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends, by region
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 South Korea
  • 10.4.5 Australia
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 UAE
  • 10.6.3 Saudi Arabia
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Aetion, Inc.
• 11.2 Cognizant Technology Solutions Corporation
• 11.3 Elevance Health, Inc.
• 11.4 Fortrea Inc.
• 11.5 ICON plc.
• 11.6 IQVIA Holdings Inc.
• 11.7 Merative
• 11.8 Optum, Inc.
• 11.9 Oracle Corporation
• 11.10 Parexel International Corporation
• 11.11 PerkinElmer Inc.
• 11.12 SAS Institute Inc.
• 11.13 Syneos Health, Inc.
• 11.14 Thermo Fisher Scientific Inc.
• 11.15 TriNetX LLC